SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is experiencing intense trading activity as market participants speculate on a potential acquisition by major tech players like Amazon, following reports of ongoing buyout talks that have triggered a massive surge in volume. The community is actively debating the implications of this possible deal, contrasting the potential buyout premium against current market valuations while weighing the company's critical role in satellite connectivity and its long-standing partnership with Apple.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is in the spotlight as investors anticipate the upcoming Artemis II mission, which marks the first crewed deep-space flight in over 50 years. The community is actively debating the stock's long-term potential within the lunar economy while closely monitoring technical price levels and market-wide volatility driven by geopolitical tensions.

Launchr is a programmable creator fee engine designed to adapt to every stage of a token’s lifecycle.  Instead of hard coded splits or one time choices, Launchr lets creators dynamically route fees in real time based on market conditions, liquidity depth, and strategy.

Launchr

Investors are actively debating the viability and longevity of the token amidst high-energy launch promotion and community efforts to drive trading volume. While some participants focus on the excitement of early-stage momentum, others are voicing caution regarding the sustainability of these types of market movements.

nCino, Inc. engages in the provision of cloud-based software applications for financial institutions in the United States and internationally. Its nCino Bank Operating System, a tenant cloud platform, digitizes, automates, and streamlines complex processes and workflow, and utilizes data analytics and artificial intelligence and machine learning (AI/ML) to enable financial institutions to onboard new clients, make loans, and manage the entire loan life cycle, open deposit and other accounts, and manage regulatory compliance. The firm's nCino IQ is an application suite that utilizes data analytics and AI/ML to provide its customers with automation and insights into their operations, such as tools for analyzing, measuring, and managing credit risk, as well as to enhance their ability to comply with regulatory requirements. The company was founded by Pierre Naudé in 2011 and is headquartered in Wilmington, NC.

Ncino Inc.

nCino is currently in focus following a significant expansion of its stock repurchase program, which has fueled positive community sentiment regarding the company's long-term capital allocation strategy. Investors and analysts are actively debating the stock's valuation after strong earnings performance and management's focus on accelerating growth in its cloud banking and AI-driven product offerings.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz Global Holdings Inc

Hertz is currently at the center of a tug-of-war between retail traders anticipating a turnaroundfueled by speculation of increased institutional involvement, potential short squeeze setups, and seasonal travel tailwindsand skeptics highlighting significant debt and earnings volatility. The community remains heavily focused on monitoring call flow and technical indicators, with intense debate over whether current price levels offer a deep-value opportunity or if the stock remains trapped by structural headwinds.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is seeing heightened volatility as retail traders speculate on a potential short squeeze, frequently comparing its low float and share structure to past parabolic meme stock runs. While some community members anticipate a massive rally based on historical spikes, others warn of significant downside risk, characterizing the activity as a high-stakes pump and dump involving extreme borrowing fees.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire is gaining attention as investors digest new contract awards and the company's expanding role in national security and NASA lunar missions. The community is actively debating the impact of ongoing insider selling by private equity firms against the stock's long-term potential in the growing space and defense sectors.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is capturing significant investor interest as the community reacts to a confirmed launch window for the BlueBird-7 satellite, serving as a critical catalyst after recent price volatility. Discussions are heavily focused on the stock's long-term infrastructure potential versus the risks of execution delays, with investors debating whether to treat recent pullbacks as prime accumulation opportunities ahead of broader sector growth.

iShares Trust - iShares U.S. Treasury Bond ETF

iShares U.S. Treasury Bond ETF

Investors are actively debating the role of GOVT and broader Treasury ETFs amid concerns over rising national debt, shifting Federal Reserve rate expectations, and increased foreign buying of U.S. government debt. Market participants are split between using these bonds as a defensive hedge against potential economic volatility and warning that current yield levels may not sufficiently compensate for long-term fiscal risks.

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals is trending as investors monitor the company's progress in expanding its obesity treatment pipeline, particularly following positive trial data and regulatory milestones for its core asset, IMCIVREE. The community remains focused on the potential for strategic M&A activity and the clinical success of upcoming candidates targeting hypothalamic obesity, which many see as a major value-driving catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HCW Biologics Secures $7M Licensing Deal for Promising Immunotherapy

HCW Biologics (NASDAQ:HCWB) finalized an exclusive worldwide licensing agreement for its fusion immunotherapeutic candidate HCW11-006, marking a meaningful step in expanding its global development strategy.

Small Cap Stocks To Keep An Eye On - March 16th

CytomX Therapeutics, HCW Biologics, Direxion Daily MU Bull 2X Shares, Meiwu Technology, and AltC Acquisition are the five Small Cap stocks to watch today, according to MarketBeat's stock screener...

Promising Pharmaceutical Stocks To Keep An Eye On - March 16th

Eli Lilly and Company, CytomX Therapeutics, Pfizer, HCW Biologics, and AbbVie are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks...

Biotech Breakthroughs and Capital Moves Drive a Busy Market Week

A wave of biotech developments, strategic financings, and emerging-technology announcements shaped market narratives this week, highlighting how innovation across biopharma, AI-driven automation, energy technology, and crypto finance continues to drive investor attention. $CTMX, $NVDA, $HCWB, $KBLB, $CYN, $BMNR, $CLIK, $CIIT, $AIRS, $DFLI

<ul class="summary-bullets"><li>HCW Biologics stated that CAR-T cells manufactured with HCW9206 were significantly superior to those manufactured with standard methods.</li><li>The company said that CAR-Ts produced with its reagent are highly enriched in long-lived T memory stem cells.</li><li>HCW Biologics added that these CAR-Ts also displayed potent activity across distinct disease experimental models, namely, HIV-1 or B-cell leukemia.</li></ul>HCW Biologics Inc. (HCWB) shares soared more than 56% in Monday’s pre-market trade after the company announced positive research results for its CAR-T cell therapy.HCW Biologics stated that HCW9206, its proprietary, commercial-stage multi-cytokine fusion protein reagent, provides a new approach to generate CAR-T cells for immunotherapy with increased function at a cost-effective price.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/HCWB">HCW Biologics</a> trended in the ‘bullish’ territory with message volumes at ‘high’ levels.<h2 class="st-heading-2">HCW9206 CAR-Ts Outperform Standard Methods, Says Company</h2>HCW Biologics stated that CAR-T cells manufactured with HCW9206 were significantly superior to those manufactured with standard methods.The company said that CAR-Ts produced using its reagent are highly enriched in long-lived T-memory stem cells. HCW Biologics added that these CAR-Ts also displayed potent activity across distinct disease experimental models, namely, HIV-1 or B-cell leukemia.“Based on experimental models, HCW9206 has shown improvement in functional activities and persistence of CAR-Ts following adoptive transfer, a goal the industry has been trying to achieve for the last decade,” said HCW Biologics CEO, Dr. Hing C. Wong.The company stated that in its study, HCW9206 helped generate long-lasting duoCAR-T cells that showed strong HIV suppression in humanized mouse models using T cells from people living with HIV. The approach could extend CAR-T therapy durability and support efforts toward a functional HIV cure, it added.<h2 class="st-heading-2">Why Are CAR-T Cells Important?</h2>CAR-T cells represent a new way to treat cancer using the patient’s own immune system. These cells genetically modify a patient’s T cells so they can recognize and attack specific cancer cells, reducing damage to healthy tissue compared with traditional treatments.Additionally, once CAR-T cells are modified and infused into a patient’s body, they multiply and continue to fight cancer.<a href="https://stocktwits.com/symbol/HCWB">HCWB stock</a> is down 47% year-to-date and 96% over the past 12 months. The Vanguard Extended Market Index Fund ETF Shares (VXF) is up 20% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/soc-stock-soars-after-sable-resumes-oil-flow-from-california-pipeline/cZ32wB1RIfi">SOC Stock Rises Pre-Market After Energy Secretary Order Restarts Sable’s California Oil Pipeline</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

HCWB Stock Soars Pre-Market On Positive Research Results For CAR-T Cell Therapy

HCW Biologics said its proprietary multi-cytokine fusion protein reagent, HCW9206, offers a cost-effective way to generate higher-function CAR-T cells for immunotherapy.

Equity

Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7R, and Others  DelveInsight

Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7R, and Others | DelveInsight Alopecia Areata Market Set to...

HCW Biologics shares logged their best session in over three months on Monday after the firm revealed progress with a new cancer drug it thinks could be a multi-billion-dollar blockbuster.The stock jumped 60.8% to $5.55 on Monday, marking its best session since May 13, before adding another 0.5% in after-hours trading.The Florida-based biotech firm said it has developed an advanced form of pembrolizumab, which is sold by Merck as Keytruda and is considered the world’s top-selling FDA-approved immune checkpoint inhibitor.Drugs in this class are designed to help the immune system fight cancer, but they often only work for a small percentage of patients, and results are not always long-lasting.HCW Biologics said its version aims to go a step further: not only releasing the “brake” on the immune system but also activating immune cells and helping them infiltrate solid tumors, such as those seen in pancreatic and ovarian cancer.&nbsp;In early lab studies and mouse models, the company states that the therapy demonstrated stronger results than Keytruda alone, at dose levels that were well tolerated.CEO Hing C. Wong noted that global sales of checkpoint inhibitors topped $40 billion in 2024, underscoring the commercial potential if effectiveness can be improved.The company also sees potential for its therapy beyond cancer. HCW Biologics said checkpoint inhibitors may help clear “senescent” cells, which are aged cells that no longer divide but drive inflammation, making them a possible tool against age-related diseases.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 538% surge in 24-hour message volume, placing it among the most trending stocks on the platform.One user noted they had already taken profits, saying they made money on $HCWB and estimated early buyers likely gained 20–30%.<stembedurl>https://stocktwits.com/Camelinvesting/message/626495258</stembedurl>Another user praised HCW Biologics’ research, suggesting that since immune checkpoint inhibitors have shown success, improving on them could be the right path forward.<stembedurl>https://stocktwits.com/everything5/message/626494404</stembedurl><a href="https://stocktwits.com/symbol/HCWB">HCW Biologics’ stock</a> has declined 68.9% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

HCW Biologics (HCWB) shares logged their best session in over three months on Monday after the firm revealed progress with a new cancer drug it thinks could be a multi-billion-dollar blockbuster. | Image source: Getty Images

HCW Biologics Stock Scores Biggest Gain Since May As Cancer Drug Breakthrough Fuels Blockbuster Hopes

The biotech firm said its next-generation version of Keytruda showed stronger results in early studies and could eventually expand into both cancer and age-related disease treatments.

HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. The firm considers age-related low-grade chronic inflammation as a contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases. The company was founded by Hing C. Wong on April 2, 2018 and is headquartered in Miramar, FL.

HCW Biologics Inc

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

Current Price	$0.30
Prev Close	$0.36
Open	$0.33
Dividend Yield	N/A
50-Day Moving Average	$0.766
Beta	0.31
Avg. Volume	22.78M
PE Ratio	-0.03

52-Week High	$17.80
52-Week Low	$0.272
Market Capitalization	$2.07M
EPS (Annual)	-$10.63
Price to Book	0.36
Revenue Per Employee	N/A

HCWB
HCW Biologics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HCWB News

HCWBHCW Biologics Inc